Tecnoloxía para a monitorización e control de Diabetes

SYSTEM AND METHOD FOR ONLINE DOMAIN ADAPTATION OF MODELS FOR HYPOGLYCEMIA PREDICTION IN DIABETES

Resumen de: US20260345089A1

Embodiments relate to an adaptive glycemia monitoring and forecasting system that includes an event monitor configured to receive blood glucose levels of an individual or information about an activity performed by the individual, and generate an event output. The system includes a control module configured to pull observation data, predictor variables, and population estimated vector of covariate weightings coefficients from a database, and generate updated estimated vector of covariate weightings coefficients for the individual user based on the event output. The updated estimated vector of covariate weightings coefficients are determined by a cross-entropy loss objective function. The updated estimated vector of covariate weightings coefficients are used to predict at least one or more of a predicted hypoglycemia state, a predicted normal glycemia state, or a predicted hyperglycemia state for the individual user.

EARLY RECOGNITION OF CHANGE TO PATHOPHYSIOLOGIC STATE OF DYSGLYCEMIA

Resumen de: US20260345090A1

Conditions of pathophysiologic dysglycemia, associated with type 1 diabetes, can be detected early, including in children. Glycemia data is collected by continuous glucose monitoring devices connected to a cloud server. The server learns person-specific patterns of glycemia and trains a model accordingly, which may serve as a baseline for comparison or as the basis for prediction of future patterns. Such models are conditioned by risk factors and various concurrent activities such as exercise and consumption of sugars. Person-specific models trained at different time periods give different simulated patterns of glycemia. Deviations between the simulated patterns, or between the predicted and actual patterns, can indicate progression of pathophysiologic dysglycemia and type 1 diabetes. These models and comparisons can be further interpreted by the software to result in a reported recommendation for additional diagnostic testing or a reported conclusion of diagnosis and recommendation of preventative intervention.

SYSTEM, METHOD, AND COMPUTER READABLE MEDIUM FOR A BASAL RATE PROFILE ADAPTATION ALGORITHM FOR CLOSED-LOOP ARTIFICIAL PANCREAS SYSTEMS

Resumen de: US20260345037A1

An insulin device configured to control insulin dosage adapts a basal rate profile, using a sensor configured to produce a blood glucose level measurement data, and detect changes of the blood glucose level measurement data over time. A processor is configured to receive the blood glucose level measurement data and a basal rate profile. A basal rate set point corresponds to an insulin delivery reference for a nominal blood glucose. The insulin device includes an insulin dispensing valve controlled by the processor to administer insulin in accordance with the received basal rate profile. The processor is configured to update the basal rate set point over a time period based on both an assessment of at least one of a risk of hyperglycemia and a risk of hypoglycemia from historical blood glucose data, and patterns of actions taken by the insulin device to mitigate glycemic risk during the time period.

BLOOD GLUCOSE RATE OF CHANGE MODULATION OF MEAL AND CORRECTION INSULIN BOLUS QUANTITY

Resumen de: US20260345904A1

Disclosed are a system, methods and computer-readable medium products that provide bolus dosage calculations by a control algorithm-based drug delivery system that provides automatic delivery of a drug, such as insulin or the like, based on sensor input. Blood glucose measurement values may be received at regular time intervals from a sensor. Using the blood glucose measurements, the control algorithm may perform various calculations and determinations to provide an appropriate bolus dosage. The appropriate bolus dosage may be used to respond to a trend in a trajectory of blood glucose measurements. In addition, a bolus dosage may also be determined by the disclosed device, system, method and/or computer-readable medium product in response to an indication that a user consumed a meal.

REDIRECTING GLUCOSE METABOLISM TO LIMIT STRESS AND IMPROVE ADOPTIVE CELL THERAPY

Resumen de: US20260345778A1

0000 Provided are improved methods for making immune effector cells, as well as improved immune effector cells generated using the methods. The improved T cells have improved respiratory capacity and mitochondrial mass. Adoptive T cell immunotherapies using such cells demonstrate improved survival, expansion, and persistence in vivo.

DEVICE AND METHOD FOR PREDICTING BLOOD GLUCOSE ON BASIS OF MULTIPLE LOGISTIC REGRESSION

Resumen de: WO2026230789A1

A device for predicting blood glucose on the basis of multiple logistic regression, according to an embodiment of the present invention, comprises: an input unit via which food information regarding a target food to be consumed by a user is input; a memory in which user information, dietary habit information, and insulin information are stored; and a processor which determines one or more first and second parameters by modeling, using first and second logistic functions respectively, a relationship between food information (a first input variable) and an increase in blood glucose and a relationship between insulin information (a second input variable) and a decrease in blood glucose, and simulates a postprandial blood glucose curve by applying the first and second parameters to derivatives of the first and second logistic functions, respectively.

System for Multi-Task Estimation of Physiological Parameters Based on Single-Lead Electrocardiogram Signals

Resumen de: US20260345053A1

0000 Cardiovascular diseases and diabetes pose significant threats to human health. Continuous monitoring of physiological parameters, including blood pressure, baroreflex sensitivity (BRS), and cardiac contractility, is critical for effective disease management. The present invention provides a multitask pipeline neural network system that utilizes a single-lead electrocardiogram (ECG), particularly a lead I ECG signal obtained from a wearable device, as an input to estimate multiple physiological parameters on a beat-to-beat basis. The system is applicable to cuffless continuous blood pressure estimation, pain assessment, bedside monitoring, and diabetes screening. Furthermore, the invention can be extended to evaluate aging indices, brain function, cardiac function, autonomic nervous system (ANS) activity, and overall cardiovascular system performance. The invention provides a scalable and market-competitive solution for home healthcare and medical industries, offering high industrial applicability and commercial value.

BLOOD GLUCOSE MONITORING MODULE WITH COMPOSITE-WAVELENGTH LIGHT SOURCE AND WEARABLE DEVICE COMPRISING THE SAME

Resumen de: US20260345035A1

0000 A blood glucose monitoring module with composite-wavelength light source and a wearable device comprising the same. The blood glucose monitoring module comprises a light-emitting component and a light-sensing component. The light-emitting component includes a plurality of light source elements configured to emit a plurality of light beams toward a subject. The light beams have wavelengths ranging from 700 nm to 1700 nm. The light beams include at least one first wavelength band and at least one second wavelength band. The at least one first wavelength band is for calibrating depth-dependent optical properties of skin tissue. The at least one second wavelength band is for detecting absorption intensity associated with blood glucose. The light-sensing component is disposed adjacent to the light-emitting component and is configured to receive diffusely reflected optical signals reflected from the subject after being illuminated by the light beams, thereby acquiring optical characteristics indicative of blood glucose concentration.

SYSTEM AND METHOD FOR GLUCOSE ESTIMATION

Resumen de: US20260345036A1

A system and method for glucose estimation. In some embodiments, a system includes: a first glucose-sensing electrode; and a second glucose-sensing electrode, the first glucose-sensing electrode and the second glucose-sensing electrode being configured to be implanted, separated by less than 5 mm, in a subject.

MODEL MOSAIC FRAMEWORK FOR MODELING GLUCOSE SENSITIVITY

Resumen de: EP4834220A1

0001 Methods, systems, and devices for modeling a relationship between glucose sensitivity and a sensor electrical property are described herein. More particularly, the methods, systems, and devices describe partitioning an input signal feature space relating glucose sensitivity and a sensor electrical property into subspaces and training a model for each subspace. For example, the subspace models may form a mosaic of models, for which the output is more accurate than a single model.

CONTINUOUS GLUCOSE MONITORS AND RELATED SENSORS UTILIZING MIXED MODEL AND BAYESIAN CALIBRATION ALGORITHMS

Resumen de: EP4834222A2

A method for monitoring blood glucose levels includes receiving a time-varying electrical signal from an analyte sensor during a temporal phase of a monitoring session and selecting a calibration model from a plurality of calibration models. The selected calibration model includes one or more calibration model parameters. The method further includes estimating at least one of the one or more calibration model parameters of the selected calibration model based on at least the time-varying electrical signal during the temporal phase and estimating the blood glucose level of the user based on the selected calibration model and the at least one estimated parameter. An apparatus and non-transitory computer readable medium can carry out similar functionality.

CONTINUOUS BLOOD GLUCOSE MEASUREMENT APPARATUS

Resumen de: EP4834208A2

0001 The present invention relates to a continuous blood glucose measurement device which is produced with an assembled body attachment unit inside an applicator so as to minimize a user s additional work of attaching the body attachment unit to the body, thereby enabling the body attachment unit to be attached to the body by simply activating the applicator, and, particularly, the present invention provides a continuous blood glucose measurement device which is provided with a wireless communication chip in a body attachment unit so as to enable communication with an external terminal, thereby enabling simple and convenient use, without additional work of connecting a separate transmitter, and easier maintenance and is activated by the user after the body attachment unit is attached to the body so as to enable the operation start time to be adjusted to an appropriate time according to user s needs, and to enable the operation to start in a stabilized state so that blood glucose can be measured more accurately.

SYSTEM AND METHOD FOR INCORPORATING EXERCISE INTO CLOSED-LOOP DIABETES THERAPY

Resumen de: WO2025145056A1

Disclosed herein are apparatuses and methods that account for exercise in closed loop insulin delivery systems. The apparatuses and methods disclosed herein address exercise-induced glucose level increases by reducing the target IOB within the closed loop. By reducing the target IOB, the algorithm responds less aggressively to pre-exercise food, and does not build up the IOB that could potentially contribute to undesirably low glucose levels once the exercise also begins lowering glucose levels. Following exercise, because the user's body will not immediately transition to a pre-exercise state, the algorithm will gradually transition back to the initial target IOB.

SYSTEMS AND METHODS FOR CALCULATING INSULIN ON BOARD IN INFUSION PUMP SYSTEMS

Resumen de: WO2025145037A1

Disclosed herein are portable infusion pump systems that provide an ability to simultaneously track insulin on board from insulin deliveries from different sources and/or of different types. A user interface can be provided to enable the user to enter insulin delivered from a source other than the portable infusion pump. A simplified calculation for estimating IOB remaining from each insulin delivery enables such calculations to be carried out with the limited memory and processing capacity of the portable infusion pump.

EXTENDED WEAR INFUSION SET WITH INCREASED INSULIN PRESERVATIVE RETENTION

Resumen de: US20250213785A1

Disclosed herein are improved infusion sets that incorporate halogenated siloxane materials within the composition of an infusion set septum. Such configurations maintain the mechanical robustness of using elastomeric materials for a fluidic septum while providing barrier properties that prevent phenolic preservative from being absorbed out of the infusion set. Infusion sets as disclosed herein are particularly suitable for maintaining insulin's anti-microbial effectiveness over extended wear (e.g., 7 days) to maintain performance of the infusion set during extended wear and reduce the risk of insulin aggregate propagation.

SYSTEMS AND METHODS FOR ENABLING AND DISABLING INSULIN PUMPS IN A MULTI-PUMP INSULIN PUMP SYSTEM

Resumen de: WO2025141541A1

Systems and methods are provided for enabling and disabling insulin pumps in a multi- pump insulin pump system. For example, multiple pumps (e.g., patch pumps) may be rotated to deliver insulin to a user. In one example, one patch pump may be worn while another patch pump is charging. Once the battery of the patch pump worn by the user is depleted, a mobile device may cause the enabled pump in operation and worn by the user to send the latest pump settings and configuration data to the mobile device which will share the information with the disabled pump. The disabled pump will then update the pump settings based on this information and the mobile device may active the pump such that is now enabled for insulin delivery. The mobile device may also facilitate pairing between the patch pumps and a CGM device as they enabled for use and disabled.

DIABETES MONITORING VIA FOOT PRESSURE ANALYSIS

Resumen de: LU505951B1

A method performed by a computer system for monitoring diabetes and comprising: a model explainability phase, comprising steps of: - collecting specific foot data from at least one sensor disposed at least within a shoe insole of a user, - collecting a plurality of trained machine learning models configured for decision-making in diabetes diagnosis based on a plurality of collected data, - based on the plurality of trained machine learning models, generating a plurality of specific machine learning models, said specific machine learning models being specified for decision-making in diabetes diagnosis based on the specific foot data, and a model reliability assessment phase, comprising steps of: - evaluating a reliability of each of the specific machine learning model based on neutrosophic sets and intuitionistic fuzzy sets, - based on the result of the evaluation step, selecting the optimized machine learning model for monitoring diabetes based on the specific foot data.

Measurement of Susceptibility to Diabetic Foot Ulcers

Resumen de: US20260334855A1

The present disclosure provides apparatuses and methods for measuring capacitance as an indication of susceptibility to the formation of a diabetic foot ulcer.

GLUCOSE SENSOR BASED ON OPEN CIRCUIT POTENTIAL (OCP) SIGNAL

Resumen de: US20260334822A1

According to some embodiments, a device for determining a glucose level of a patient comprises a set of electrodes comprising a first working electrode, a second working electrode, a counter electrode, and a reference electrode; and one or more processors. The one or more processors may be configured to: determine a sensor signal based on current flowing between the first working electrode and the counter electrode; determine an open circuit potential (OCP) signal based on a voltage across the second working electrode and the reference electrode while the second working electrode is in an OCP measurement mode and while the first working electrode is in a measurement mode for measuring the sensor signal indicative of the glucose level of the patient; and determine the glucose level of the patient based on the sensor signal and the OCP signal by correcting the sensor signal based on the OCP signal.

CELL MACROENCAPSULATION DEVICES, METHOD OF FABRICATION AND USE THEREOF

Resumen de: US20260337551A1

It is provided a cell macroencapsulation device for implanting cells in a recipient comprising cells encapsulated in a porous membrane, wherein the porous membrane consists of a sugar network coated with a polymeric solution comprising porogen, which can be used as a graft to transplant islets while protecting the graft from the immune system as well as providing enhanced convection and diffusion to ensure long-term cell survival and physiological insulin delivery.

MEASUREMENT DEVICE AND MEASUREMENT METHOD

Resumen de: US20260334821A1

The present technology relates to a measurement device that enables accurate measurement of the concentration of glucose (glucose sugar) contained in a measurement target, and a measurement method. The glucose concentration in the measurement target is calculated on the basis of the complex dielectric constant of the measurement target and the moisture content of the measurement target. The moisture content can be calculated on the basis of an incident signal as an electromagnetic wave that has entered the measurement target, and a reflected signal reflected from the measurement target with respect to the incident signal.

Automatically or manually initiated meal bolus delivery with subsequent automatic safety constraint relaxation

Resumen de: AU2026249025A1

The exemplary embodiments may provide a drug delivery device that receives glucose level values for a user (e.g., a diabetic patient) and based on the glucose level values, determines when the user has consumed a meal. In some embodiments, the drug delivery device may calculate an appropriate bolus dose and automatically deliver the drug bolus to the user. In some embodiments, instead of detecting the meal, the user may announce the meal, such as by activating an element on the drug delivery device or on a management device for the drug delivery device. Responsive to the meal announcement, the drug delivery device may calculate the drug bolus dose and deliver the drug bolus. In conjunction with the delivery of the drug bolus, the drug delivery device may relax one or more safety constraints for a relaxation period following the drug bolus delivery so that additional basal drug may be delivered, if needed, under relaxed constraints. ct c t

SYSTEMS AND METHODS FOR DYNAMICALLY AND INTELLIGENTLY MONITORING A HOST'S GLYCEMIC CONDITION AFTER AN ALERT IS TRIGGERED

Resumen de: US20260334889A1

Systems and methods for providing sensitive and specific alarms indicative of glycemic condition are provided herein. In an embodiment, a method of processing sensor data by a continuous analyte sensor includes: evaluating sensor data using a first function to determine whether a real time glucose value meets a first threshold; evaluating sensor data using a second function to determine whether a predicted glucose value meets a second threshold; activating a hypoglycemic indicator if either the first threshold is met or if the second threshold is predicted to be met; and providing an output based on the activated hypoglycemic indicator.

ANALYTE SENSORS AND METHODS FOR IMPROVING INTERFERENT REJECTION AND LONGEVITY

Resumen de: US20260338727A1

An analyte sensor includes a microcontroller, a base layer, a conductive layer disposed on the base layer where the conductive layer includes a working electrode configured to provide a current signal in presence of glucose, an interference rejection membrane (“IRM”) layer disposed on the working electrode where the IRM layer is negatively charged, and an enzyme layer disposed on the IRM layer where the enzyme layer includes an enzyme selected to generate a detectable electrical signal upon exposure to the glucose. The microcontroller is configured to process an electrochemical impedance spectroscopy (EIS) parameter to determine a state of the IRM layer.

ACCURACY CONTINUOUS GLUCOSE MONITORING METHOD, SYSTEM, AND DEVICE

Nº publicación: US20260334823A1 29/10/2026

Solicitante:

UNIV OF VIRGINIA PATENT FOUNDATION [US]
University of Virginia Patent Foundation

Resumen de: US20260334823A1

A method, system, and device for improving the accuracy of a continuous glucose monitoring sensor by estimating a CGM signal at a time t+PH using a value of CGM at time t, using a real-time short-time glucose prediction horizon to estimate the real time denoised CGM value with a noise estimation algorithm.